Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application.

Abstract : Mesenchymal stromal cell (MSC)-based therapy holds great promise for treating immune disorders and for regenerative medicine in agreement with their paracrine trophic and immunosuppressive activities. Various processes have been developed worldwide to produce clinical grade MSCs but, so far, it is not known if one given MSC is more efficient than another. In addition, while their broad activity on innate and adaptative immune cell subsets is now widely admitted, the precise mechanisms supporting their immunoregulatory capacities are still a matter of debate. Finally, quantitative immunological potency assays correlated to clinical efficacy and clinically relevant immunomonitoring approaches for MSC-treated patients are sorely needed. Multiple parameters could influence the immunomodulatory potential of therapeutic MSCs. The most important challenge is now to differentiate, within a high number of poorly comparable and even contradictory pre-clinical studies, the parameters that could have some clinical impact from those that are only due to uncontrolled experimental variability. Importantly, besides MSC-related differences, primarily linked to production processes, several important variables associated with immune assays themselves, including selection of effector immune cells, activation signals, and read-out techniques, should be carefully considered to obtain solid results with potential therapeutic application. In this review, we establish a core of common and reproducible immunological properties of MSCs, shed light on technical issues concerning immunomodulatory potential assessment, and put them into perspective when considering clinical application.
Type de document :
Article dans une revue
Stem Cell Research and Therapy, BioMed Central, 2013, 4 (3), pp.64. 〈10.1186/scrt214〉
Liste complète des métadonnées

Littérature citée [48 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00868889
Contributeur : Morgane Le Corre <>
Soumis le : mercredi 2 octobre 2013 - 10:25:03
Dernière modification le : mercredi 16 mai 2018 - 11:23:19
Document(s) archivé(s) le : lundi 6 janvier 2014 - 09:55:24

Fichier

scrt214.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Cédric Ménard, Karin Tarte. Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application.. Stem Cell Research and Therapy, BioMed Central, 2013, 4 (3), pp.64. 〈10.1186/scrt214〉. 〈inserm-00868889〉

Partager

Métriques

Consultations de la notice

224

Téléchargements de fichiers

194